MUSE Microscopy, Inc., a innovator in digital pathology announced it’s in their final phase. After a strategic acquisition by the current leadership team in 2021, MUSE has steadfastly pursued a visionary roadmap that has the potential to reshape the future of digital pathology. Today, that journey reaches an exciting moment with SmartPath MUSE Technology (SmartPath)—the industry’s first tissue-to-digital imager using MUSE (Microscopy with Ultraviolet Surface Excitation) technology, intended to create a solution that eliminates the need for traditional slide-based histology, a fundamental process that has remained unchanged for over a century.
SmartPath’s objective of this advanced imager is to provide new technology that rapidly captures high-resolution ultraviolet images, directly from whole fresh or formalin-fixed (non-FFPE) tissue, and convert these UV images to detailed H&E-like digital images for pathologist’s review. Utilization of non-caustic fluorescent dyes on fresh tissue significantly improves RNA retained in the sample for downstream processing. This first of its kind imager implements a simple workflow, with the goal of bringing unprecedented efficiency to aid pathologists in diagnostic pathology labs worldwide. By eliminating cumbersome manual processes, SmartPath has the potential to propel pathology into the digital age and support a wide range of global IVD applications and market segments.
Matthew Nuñez, CEO of MUSE Microscopy, Inc., expressed the company’s enthusiasm about this landmark achievement: “We are immensely proud of the advancements we’ve made with SmartPath—a groundbreaking tissue-to-digital imager that redefines where true digital pathology starts. This moment signifies more than just a new product; it represents the potential for a fundamental transformation for the entire field of pathology, empowering professionals to move past legacy processes that have constrained advancements in workflow and diagnostics for far too long. With SmartPath, we are intent on setting a new standard and opening doors to the next generation of aids in pathology.”
Transforming a Long-Standing Pathology Workflow
The SmartPath Imager tackles one of pathology’s most persistent challenges: the dependence on traditional glass slide histology. By leveraging rapid tissue-to-digital imaging technology, SmartPath seeks to transform pathology, from analog slide-based processes to a seamless and effective workflow that provides high-resolution digital tissue images to pathologists, without destructive direct-to-digital sample preparation.
The statements made regarding the SmartPath Imager have not been evaluated by the Food and Drug Administration (FDA). The SmartPath System is currently intended for research use only. This medical device has not yet been evaluated or cleared by the FDA. Its safety and effectiveness have not been established nor confirmed by FDA-approved research. SmartPath is not currently available for sale in the United States as a diagnostic aid or medical device for human pathology. This material is provided solely for informational purposes and does not substitute for professional medical advice. It also does not constitute an offer to promote the device for any medical use.
